MIP Discovery raises £7 million to advance cell and gene therapy solutions
MIP Discovery, a biotechnology company that develops non-biological affinity reagents for cell and gene therapy applications, has secured a £7 million Series A funding round led by Mercia Ventures. The round also saw participation from existing investor Calculus Capital and…